

14th Annual Pacific Psychopharmacology Conference



**Join us for our most impressive line-up of speakers
ever, all from the comfort of your office or home.**

Our usual in-person conference will be going completely virtual this year and will feature international experts on depression, anxiety, schizophrenia, and evolving approaches to the psychiatric impacts of COVID-19. And as always, we will offer local expertise on other important topics in psychopharmacology. We look forward to your participation online in September.

Register at ubccpd.ca/course/pppc2020

📍 6.5 MOC Section 1, Mainpro+

🕒 Friday, September 25, 2020

📍 Broadcast online from
Vancouver, Canada

👤 Psychiatrists, Primary Care Physicians,
Pharmacists, Psychologists, Nurse
Practitioners, Nurses, Social Workers

🐦 #PPPC2020

Accredited by:



UBC CPD
Medicine

**CONTINUING
PROFESSIONAL
DEVELOPMENT**

Friday, September 25, 2020

0800 - 0805	Welcome and Opening Remarks	Dr. Randall White
0805 - 0845	Antidepressants for Major Depression	Dr. Andrea Cipriani
0845 - 0900	Q&A Session	
0900 - 0940	The Role of Esketamine and Emerging Rapid Acting Antidepressants	Dr. Roger McIntyre
0940 - 0955	Q&A Session	
0955 - 1025	Alcohol Use Disorder Guidelines	Dr. Rupinder Brar
1025 - 1040	Q&A Session	
1040 - 1100	AM Break	
1100 - 1130	Anxiety, Depression and Neuropsychiatric Disorders in Older Adults	Dr. Zahinoor Ismail
1130 - 1145	Q&A Session	
1145 - 1215	Evaluation and Treatment of Hospitalized Patients with CoVID-19	Dr. Damir Huremovic
1215 - 1230	Q&A Session	
1230 - 1300	Lunch Break	
1300 - 1345	CONCURRENT SESSIONS I	
A)	Don't Worry, You've Got This! Management of Pediatric Anxiety Disorders	Dr. Dean Elbe
B)	Post CoVID-19 Psychiatric Outcomes	Dr. Damir Huremovic
C)	When Meth and Psychosis Come Together	Dr. Julius Elefante Mr. Reza Rafizadeh
1345 - 1400	PM Break	
1400 - 1445	CONCURRENT SESSIONS II	
D)	Substance Use Disorders through an Occupational Lens	Dr. Charl Els
E)	Vaping and E-cigarettes	Dr. Milan Khara
F)	Buprenorphine as a Monthly Long Acting Injection: A new treatment option for opioid use disorder	Dr. Nader Sharifi Dr. Tamara Mihic
1445 - 1450	Quick Break	
1450 - 1530	Antipsychotic Therapy	Dr. John Kane
1530 - 1545	Q&A Session	
1545	Closing Remarks	Dr. Jacky Siu

Faculty Presenters



Andrea Cipriani, MD, PhD

Professor of Psychiatry; NIHR Research Professor; Director, Clinical Research Facility, Warneford Hospital, Oxford; Associate Director, R&D, Oxford Health NHS Foundation Trust, Oxford



Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology, University of Toronto; Head, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto; Executive Director, Brain and Cognition Discovery Foundation, Toronto



John Kane, MD

Chairman of Psychiatry, Zucker Hillside Hospital, NY. Chairman, Psychiatry and Professor of Psychiatry & Molecular Medicine, Hofstra North Shore-LIJ School of Medicine



Zahinoor Ismail, MD, FRCPC

Associate Professor, Community Health Sciences, Psychiatry, Hotchkiss Brain Institute, University of Calgary; Principal Investigator, Ron & Rene Ward Centre for Healthy Brain Aging Research




Damir Huremovic, MD, MPP

Assistant Professor, Donald & Barbara Zucker School of Medicine, Hofstra/Northwell; Psychiatrist, Nassau University Medical Center East Meadow, NY



Charl Els, MD, FRCPC

Clinical Professor, Department of Psychiatry, University of Alberta; Chair, Occupational and Environmental Medical Association of Canada's Guideline Committee



Milan Khara, MD, CCFP, MBChB

Clinical Assistant Professor, University of British Columbia, Faculty of Medicine; Medical Lead, Vancouver General Hospital Smoking Cessation Clinic




Nader Sharifi, MD, CCFP

Addiction Medicine Lead, BC Mental Health & Substance Use Services; Medical Director, Correctional Health Services, Provincial Health Services Authority



Rupinder Brar, MD, CCFP, CSIAM

Canada Addiction Medicine Research Fellow, BC Mental Health & Substance Use Services; Primary Care Physician, PHS Community Services Society; Clinical Instructor, Dept of Family Practice, UBC




Julius Elefante, MD, FRCPC

Clinical Instructor, Department of Psychiatry, University of British Columbia; Staff Psychiatrist & Addiction Specialist, Providence Health Care




Dean Elbe, PharmD, BCPP

Clinical Pharmacy Specialist, Child & Adolescent Mental Health, BC Children's Hospital, Provincial Health Services Authority; Associate Member, Department of Psychiatry, University of British Columbia



Reza Rafizadeh, BScPharm, ACPR, BCPP

Clinical Pharmacy Specialist, Mental Health & Substance Use, Burnaby Centre for Mental Health & Addiction, BC Psychosis Program, Lower Mainland Pharmacy Services



Tamara Mihic, PharmD, ACPR, BCPP

Clinical Pharmacy Specialist, Opioid Stewardship, St. Paul's Hospital, Vancouver; Clinical Instructor, Faculty of Pharmaceutical Sciences, University of British Columbia

Registration Fees

Register at ubccpd.ca/course/pppc2020

	By August 17	After August 17
Delegates	\$225	\$250
Residents & Students	\$50	\$75

Fees include access to the live virtual event, all available materials, and post-webinar recording.

Cancellations: No refunds or transfers, unless you cancel in writing to cpd.info@ubc.ca by September 18, 2020. A \$25.00 processing fee will apply.

Cancellations by the organizers: The Division of Continuing Professional Development reserves the right to cancel an educational program thirty (30) calendar days prior to the course date. Each registrant will be notified by email, followed by a full refund.

Accreditation

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians.

This course has been reviewed and approved by the UBC Division of Continuing Professional Development. This group learning course meets the certification criteria of the College of Family Physicians of Canada and has been certified by UBC CPD for up to **6.5 Mainpro+** credits.

This course is an accredited group learning activity eligible for up to **6.5 MOC Section 1** credits as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Each physician should claim only those credits he/she actually spent in the activity.

Pharmacy Note:

Mainpro+ credits are directly transferable to the College of Pharmacists of British Columbia's Professional Development and Assessment Program (PDAP). For participants outside of BC, please check with your provincial regulating body on which continuing education credits are deemed acceptable.

Planning Committee

Randall F. White, MD, FRCPC. [PPPC 2020 Committee Co-Chair](#); Medical Director, Vancouver Community Mental Health Services; Clinical Director, BC Psychosis Program; Clinical Professor, Department of Psychiatry, UBC

Jacky Siu, BScPharm, ACPR, PharmD, BCPP. [PPPC 2020 Committee Co-Chair](#); Clinical Pharmacy Specialist, Tertiary Mental Health & Substance Use, Vancouver General Hospital; Clinical Assistant Professor, Faculty of Pharmaceutical Sciences, UBC

Annemarie Falk, MD, CCFP, FCFP. Clinical Associate Professor, Department of Family Practice, UBC; Tertiary Mental Health, Vancouver General Hospital

Nick Mathew, MD, FRCPC, MSc, ABPN (Addiction Psychiatry), dipABAM. Addiction Division Lead, Surrey Memorial Hospital; Member, Pain Medicine Residency Training Committee; Clinical Assistant Professor, Department of Psychiatry, UBC

Tamara Mihic, BScPharm, PharmD, ACPR, BCPP. Clinical Pharmacy Specialist, Opioid Stewardship, St. Paul's Hospital, Vancouver; Clinical Instructor, Faculty of Pharmaceutical Sciences, UBC

Reza Rafizadeh, BScPharm, ACPR, BCPP, RPh. Clinical Pharmacy Specialist, Mental Health & Substance Use, Burnaby Centre for Mental Health & Addiction, BC Psychosis Program, Lower Mainland Pharmacy Services

